ERBB2 and cancer: The success of trastuzumab is attributed to multiple mechanisms that involve antibody binding to HER2 on the cancer cell membrane [reviewed by ref (96): it prevents homo- and heterodimerization, thus inhibiting the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K/Akt) pathways.